TCTR20230109005已完成1 期
A Bioequivalence Study of Two Formulations of Apixaban 5-mg Film-coated Tablets in Healthy Thai Subjects under Fasting Conditions
T.O. Chemicals (1979) Ltd.0 个研究点目标入组 26 人开始时间: 2023年1月9日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1. Thai Male/Female must be 18-55 years of age, body weight more than 50.0 kg with body mass index (BMI) of 18.0-30.0 kg/m2, inclusive
- •2. Must be in good health as determined by medical history, vital signs (blood pressure (systolic blood pressure not lower than 90 or not over 139 mmHg, diastolic blood pressure not lower than 60 or not over 89 mmHg), body temperature, pulse rate, respiratory rate) and physical examination or showing no clinically significant abnormalities in the opinion of Principal/Clinical Investigator or designated physicians
- •3. Screening electrocardiogram (ECG) without clinically significant abnormalities
- •4. Screening visit laboratory values of blood test including hematology (complete blood count (CBC) with differential), fasting blood sugar (FBS), blood urea nitrogen (BUN), creatinine (Cr), creatinine clearance (CrCl) (calculated) and liver function test (aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin and alkaline phosphatase (ALP)) must be within the normal range or showing no clinically significant abnormalities in the opinion of Principal/Clinical Investigator or designated physicians
- •5. Prothrombin time (PT), activated partial thromboplastin time (aPTT), and international normalized ratio (INR) should be within normal range or showing no clinically significant abnormalities in the opinion of Principal/Clinical Investigator or designated physicians at screening visit and prior to dosing at Period 2
- •6. Urinalysis results within normal limit or showing no clinically significant abnormalities in the opinion of Principal/Clinical Investigator or designated physicians
- •7. Must have serum hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV) and human immunodeficiency virus antibody (anti-HIV) negative
- •8. Female subject must have serum beta-subunit of human chorionic gonadotropin negative.
- •9. Female subject of childbearing potential or male subject agrees to use an acceptable birth control method from visit 1 to the follow-up visit. The acceptable birth control method is defined as a barrier method of contraception (including condoms, intrauterine device and diaphragm with spermicidal agent) or total abstinence from sexual intercourse from visit 1 to the follow-up visit. Hormonal contraceptives are not acceptable.
- •10. Female subject of non-childbearing potential (hysterectomy, both ovaries removed, surgically sterilized or postmenopausal (for at least 12 consecutive months of amenorrhea)).
- •11. Female subject must agree not to become pregnant for the entire participation period and must have a negative result for a urine pregnancy test performing prior to dosing at Period 1 and Period 2.
- •12. Non-smoker (never smoked or no smoking within the previous 1 year)
- •13. Refrain from using herbal medications, cannabis containing products, dietary supplements (e.g., St. Johns Wort, ginkgo biloba, garlic supplements), vitamins, grapefruit or grapefruit juice, or pomelo within 14 days before the first administration of investigational product
- •(Day 1). Subjects must agree to refrain from these items until the last collection time-point of Period 2.
- •14. Subject must have ended any systemic medications or any medications that have any impact on gastrointestinal system at least 30 days prior to Day 1 or at least 5 times of elimination half-life prior to Day 1 and agree to continue their refraining throughout the follow-up period.
- •15. Subject does not receive C
排除标准
- •1. Known hypersensitivity to apixaban or any other similar class of drugs or its components
- •2. Past medical history of renal and hepatic insufficiency
- •3. Subject has a history of any illness that, in the opinion of Principal/Clinical Investigator or designated physicians, might confound the result of the study or pose an additional risk in administering investigational product to the subject. This may include but is not limited to: a history of relevant drug or food allergies; history of cardiovascular, gastrointestinal, central nervous system disease, renal and hepatic impairment; history or presence of clinically significant illness; or history of mental illness that may affect compliance with study requirements.
- •4. Have a history of significant hemorrhage within 6 months
- •5. Known of coagulation disorders (this may include but is not limited to hemophilia) or sensitive to common cause of bleeding
- •6. Have condition associated with an increase risk of bleeding. This may include but is not limited to: periodontitis, hemorrhoids, acute gastroenteritis and acute peptic ulcer.
- •7. Have CrCl (calculated) less than or equal to 50 mL/min
- •8. Have history of drug abuse (in the opinion of Principal/Clinical Investigator or designated physicians, as judged by medical history) in the last 12 months
- •9. Have positive result of urine drug abuse testing on opioids (morphine (Mor), methadone (MTD)), cannabinoids (tetrahydrocannabinol (THC)), methamphetamine (Meth), cocaine (Coc) or methylenedioxy-methamphetamine (MDMA) at screening visit or before dose administration at each period
- •10. Alcohol abuse or excessive use (in the opinion of Principal/Clinical Investigator or designated physicians, as judged by medical history) in the last 12 months
- •11.Have positive result of alcohol breathing test at screening visit or before dose administration at each period
- •12.Female subject is pregnant or breast feeding.
- •13.Difficulties fasting or consuming standard meals
- •14.Difficulties swallowing whole tablets
- •15.Donation or loss of whole blood:
- •a. More than or equal to 50 mL and less than or equal to 499 mL within 30 days prior to Day 1
- •b. More than or equal to 500 mL within 56 days prior to Day 1
- •16.Participation in any investigational drug study within 30 days from screening visit (from the last follow-up visit to the screening visit). Subject who participates in COVID-19 vaccine trial that does not have any intervention during the course of this study (from the expected enrollment date to the expected follow-up visit) can be included in this study.
研究者
相似试验
尚未招募
1 期
A Bioequivalence Study of Two Formulations of Apixaban 5-mg Film-coated Tablets in Healthy Thai Subjects under Fasting ConditionsPrevention of venous thromboembolism in adult patients who have undergone elective hip or knee replacement surgery, treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), prevention of recurrent DVT and PE, prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.Bioequivalence, apixaban, generic apixaban, pharmacokineticsTCTR20240811001SciGen Pte. Ltd.26
尚未招募
1 期
A Bioequivalence Study of Two Formulations of Atorvastatin Calcium Equivalence to Atorvastatin 40-mg Tablets in Healthy Thai Volunteers under Fasting Conditioipid lowering agentAtorvastatin,BioequivalenceTCTR20190902003ovartis (Thailand) Ltd.48
尚未招募
不适用
Comparative bioequivalence study of the Apixaban 5-mg Tablets manufactured by Darman Yab Darou Company-.IRCT20130313012810N10Darman Yab Darou Pharmaceutical Company24
已完成
不适用
Comparative in vivo evaluation of 2 ?Apixaban 5 mg Tablet formulations.IRCT20180620040164N37Actover Pharmaceutical Co.24
招募中
Unknown
Investigating the in vivo bioequivalence of Apixaban tabletIn the present study, the products will be administered to healthy volunteers..IRCT20220211053992N10Tabriz University of Medical Sciences24